Immunovant, Inc. (IMVT)
NasdaqGS - NasdaqGS 即時價格。貨幣為 USD。
加入追蹤清單
收市：04:00PM EDT
收市後：
正在載入互動式股價圖表...
- Insider Monkey
Should You Hold Immunovant (IMVT)?
Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here. The fund advanced 8.92% (Institutional Shares) in the quarter compared to an 8.52% gain for the Russell 3000 Health Care Index (benchmark) and a 10.56% increase for the S&P […]
- Zacks
Here's Why You Should Add Immunovant (IMVT) to Your Portfolio
Immunovant's (IMVT) late-stage studies evaluating its lead candidate, batoclimab, for various autoimmune indications are progressing well. Several data readouts are expected in 2024 and 2025.
- Zacks
What Makes Immunovant (IMVT) a New Buy Stock
Immunovant (IMVT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
